Medipal Holdings Corporation · TSE:7459
Medipal — Q3 FY2025 Earnings Presentation
15 slides from Medipal's earnings presentation, Feb 9, 2026
Slide 1: Financial Results for the Third Quarter Ended December 31, 2025
February 9, 2026 Financial Results for the Third Quarter Ended December 31, 2025 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” an Orchestra in Support of People's Health The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being an
Slide 2: Overview of Financial Results for 3Q/FY2025
Overview of Financial Results for 3Q/FY2025 Our Core businesses remain strong, and we are strengthening and implementing future-oriented growth strategies to achieve sustainable growth Each business segment is progressing as planned in line with its respective full-year forecasts Net Sales︓Consoli
Slide 3: 3Q/FY2025 Consolidated Statements
3Q/FY2025 Consolidated Statements （¥ billion) 3Q/FY2024 3Q/FY2025 Results Results YoY [% of Net Sales] [% of Net Sales] YoY Change % of Change Net Sales 2,807.1 2,911.6 +104.4 +3.7% Gross Profit 194.2 199.0 +4.7 +2.5% [6.92％] [6.84％] [(0.08pp)] 148.8 155.8 +6.9 +4.7% SG&A Expenses [5.30%] [5.35％] [+
Slide 4: 3Q/FY2025 Consolidated Results
3Q/FY2025 Consolidated Results Gross profit increased due to the sales growth, but operating profit decreased* due to the impact of business investment expenses, etc. Profit attributable to owners of parent rose due to an increase in non-operating income and the recording of extraordinary income and
Slide 5: Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit （¥ billion) +1.4 SG＆A expenses（Increase） Non-Operating Income/Expenses Profit from MEDICEO (6.9) +6.7 +3.4 Profit from PALTAC Business Gain on investment costs investments in of MEDICEO investment Others partnerships*
Slide 6: Factors behind YoY changes in Ordinary Profit, Profit before Income Taxes, and Profit
Factors behind YoY changes in Ordinary Profit ,Profit before Income Taxes, and Profit attributable to Owners of Parent Extraordinary Income/Expenses （¥ billion) (3.9) Gain on sale Business restructuring of investment expenses related to securities logistics operations* +0.8 (4.5) +4.6 Profit attribu
Slide 7: 3Q/FY2025 MEDICEO Business
3Q/FY2025 MEDICEO Business (¥ billion) 3Q/FY2024 3Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 1,809.7 1,875.0 +65.3 +3.6% Gross Profit 113.7 115.2 +1.4 +1.3% [6.29%] [6.14%] [(0.14pp)] SG&A Expenses 92.9 96.3 +3.4 +3.7% [5.13%] [5.14%] [+0.01pp] SG
Slide 8: 3Q/FY2025 MEDICEO Business
3Q/FY2025 MEDICEO Business Initiatives utilizing the two As (ALC and AR*) have been highly praised by medical institutions and dispensing pharmacies, resulting in sales exceeding market growth Gross profit and adjusted operating profit※ increased Amount YoY Change Change factors from 3Q/2024 • Presc
Slide 9: 3Q/FY2025 PALTAC Business
3Q/FY2025 PALTAC Business (¥ billion) 3Q/FY2024 3Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 911.0 950.6 +39.5 +4.3% 68.0 71.4 +3.4 Gross Profit +5.0% [7.47%] [7.52%] [+0.05pp] SG&A 45.5 49.4 +3.9 +8.6% Expenses [5.00%] [5.21%] [+0.20pp] Operating
Slide 10: 3Q/FY2025 PALTAC Business
3Q/FY2025 PALTAC Business Sales and gross profit showed growth, while SG&A expenses rose due to increased investment in human resources, etc. Net Sales Increased due to supported by higher transactions volumes and the expansion of new products. However, higher SG＆A expenses resulting from rising lab
Slide 11: 3Q/FY2025 AGRO&FOOD Business
3Q/FY2025 AGRO&FOOD Business (¥ billion) 3Q/FY2024 3Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 89.4 88.9 (0.4) (0.5％) Gross Profit 12.4 12.4 (0.0) (0.6%) [13.97%] [13.95%] [(0.02pp)] SG&A Expenses 10.5 10.2 (0.2) (2.3%) [11.76%] [11.55%] [(0.21pp)
Slide 12: 3Q/FY2025 AGRO&FOOD Business
3Q/FY2025 AGRO&FOOD Business Despite higher costs arising from exchange rates, operating profit increased, supported by lower SG＆A expenses On January 30, MP AGRO CO., LTD. completed the acquisition of Cygni Corporation , a company with strengths in the EC business in the companion animal market. Ai
Slide 13: Forecast of Consolidated Results for the FY2025
Forecast of Consolidated Results for the FY2025 Due to the impact of non-operating income and extraordinary income & losses not included in the forecast of consolidated results for the FY2025, ordinary income and net income attributable to owners of the parent exceeded expectations as of the third q
Slide 14: Management Philosophy
Management Philosophy Contributing to peopleʼs health and the advancement of society through creation of value in distribution Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 13
Slide 15: Forward-Looking Statements
【Forward-Looking Statements】 These materials reflect analysis of available information and various trends as of the date on the cover. Risks and uncertainties affecting the Companyʼs business could cause actual results to differ materially from any projections presented in these materials. In the ev